AIMOVIG IS THE MOST PRESCRIBED ANTI CGRP WORLDWIDE AND IN THE UAE[1]

MORE THAN 728,000 PATIENTS WORLD WIDE[2]

GIVE THEM BACK THEIR DAYS AND WEEKS, YEAR AFTER YEAR.

AIMOVIG. SUSTAINED MIGRAINE PREVENTION.[3-4]

Date of preparation: September 2021 151677

Aimovig (erenumab) is indicated for prophylaxis of migraine in adults.[1]

References

1. IQVIA Local Market Share data as of November 2022
2. Novartis third quarter and nine month 2022 condensed interim financial report - supplementary data.
3. Tepper SJ et al. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020 May;40(6):543-553.
4. Peter J. Goadsby et al. Long-term Efficacy and Safety of Erenumab Results From 64 Weeks of the LIBERTY Study. Neurology Jun 2021, 96 (22) e2724-e2735.

BSS
Regulatory Affairs
AIMOVIG® (erenumab)
70 mg/mL Solution for injection in a prefilled autoinjector/pen
140 mg/mL Solution for injection in a prefilled autoinjector/pen
Basic Succinct Statement (BSS)
Version 2.4
Effective date: 05-Oct-2020
Safety Label Change (SLC) Tracking Number: 2020-PSB/GLC-1156-s
Document status: Final

Important note: Before prescribing, consult full prescribing information.
Composition: Solution for injection for subcutaneous use 1 pre-filled pen of 1 ml contains 70 mg or 140 mg of Erenumab.
Indication: Prophylactic treatment of migraines in adults, if indicated.
Dosage and Administration: One Aimovig dose of 70 mg as a subcutaneous injection once a month is recommended. In patients who display unsatisfactory response to this dose, the dose may be increased to 140 mg once a month, as long as a better effect is proven.
Contraindication: Hypersensitivity reactions to the active substance or to any of the excipients according to the composition.
Warnings and Precautions: The removable cap contains dry natural rubber latex, which can cause allergic reactions. Severe hypersensitivity reactions including rash, angioedema and anaphylactic reactions were reported with Aimovig since market introduction. Constipation with severe complications may occur when using Aimovig. Patients taking Aimovig should there fore be monitored for signs of severe constipation and be clinically treated accordingly. The simultaneous use of drugs that are associated with reduced gastrointestinal motility may elevate the risk of severe constipation and potential complications. The safety and efficacy of Aimovig in children and adolescents has not been studied. There is no safety information for patients with certain severe cardiovascular diseases. Aimovig should not be used during pregnancy and while breast-feeding, unless this is clearly required.
Interactions: Aimovig displayed no influence on the pharmacokinetics of sumatriptan, as well as an oral combination preparation for contraception that contains ethinyl estradiol and norgestimate. Erenumab is not metabolized by cytochrome P450 enzymes, so interactions with substrates, inducers and inhibitors of cytochrome P450 enzymes are unlikely.
Adverse Effects: Common: Constipation, itching, muscle cramps, reactions at the injection site (pain, erythema or itching).
Pack Sizes: Country-specific.
Legal classification: Country-specific.
BSS Version: v2.4
Leaflet date: April 2021

aimovig™
erenumab